Banco de Sabadell S.A Boosts Position in Amgen Inc. (NASDAQ:AMGN)

Banco de Sabadell S.A lifted its stake in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 16.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,367 shares of the medical research company’s stock after acquiring an additional 776 shares during the period. Banco de Sabadell S.A’s holdings in Amgen were worth $1,206,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Gryphon Financial Partners LLC boosted its stake in shares of Amgen by 4.4% in the 4th quarter. Gryphon Financial Partners LLC now owns 1,040 shares of the medical research company’s stock valued at $234,000 after buying an additional 44 shares during the period. Formidable Asset Management LLC lifted its stake in Amgen by 1.9% during the fourth quarter. Formidable Asset Management LLC now owns 2,376 shares of the medical research company’s stock worth $541,000 after purchasing an additional 45 shares during the last quarter. Sierra Capital LLC lifted its stake in Amgen by 7.1% during the fourth quarter. Sierra Capital LLC now owns 678 shares of the medical research company’s stock worth $153,000 after purchasing an additional 45 shares during the last quarter. Covenant Asset Management LLC lifted its stake in Amgen by 1.0% during the fourth quarter. Covenant Asset Management LLC now owns 4,723 shares of the medical research company’s stock worth $1,063,000 after purchasing an additional 47 shares during the last quarter. Finally, Old North State Trust LLC lifted its stake in Amgen by 3.4% during the fourth quarter. Old North State Trust LLC now owns 1,492 shares of the medical research company’s stock worth $336,000 after purchasing an additional 49 shares during the last quarter. Institutional investors and hedge funds own 79.01% of the company’s stock.

NASDAQ:AMGN opened at $255.26 on Friday. The firm has a market cap of $136.36 billion, a P/E ratio of 25.12, a PEG ratio of 1.71 and a beta of 0.58. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. The stock’s 50 day simple moving average is $245.05 and its 200-day simple moving average is $229.97. Amgen Inc. has a 12-month low of $198.64 and a 12-month high of $258.45.

Amgen (NASDAQ:AMGNGet Rating) last released its earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.22 by $0.03. Amgen had a return on equity of 165.95% and a net margin of 21.75%. The business had revenue of $6.24 billion for the quarter, compared to analyst estimates of $6.09 billion. During the same quarter in the previous year, the company posted $3.70 earnings per share. Research analysts forecast that Amgen Inc. will post 17.48 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 8th. Investors of record on Tuesday, May 17th will be issued a dividend of $1.94 per share. This represents a $7.76 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend is Monday, May 16th. Amgen’s dividend payout ratio is presently 76.38%.

AMGN has been the subject of several recent analyst reports. Mizuho boosted their target price on Amgen from $202.00 to $208.00 in a research note on Tuesday, May 10th. Morgan Stanley decreased their target price on Amgen from $238.00 to $237.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 12th. StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 16th. Piper Sandler boosted their price objective on Amgen from $255.00 to $260.00 in a research note on Thursday, April 28th. Finally, Barclays boosted their price objective on Amgen from $233.00 to $236.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $243.07.

In other Amgen news, Director R Sanders Williams sold 600 shares of the company’s stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $250.00, for a total value of $150,000.00. Following the sale, the director now owns 5,501 shares of the company’s stock, valued at $1,375,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 13,500 shares of the company’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total value of $3,264,435.00. Following the completion of the sale, the executive vice president now directly owns 37,333 shares in the company, valued at approximately $9,027,492.73. The disclosure for this sale can be found here. Corporate insiders own 0.46% of the company’s stock.

Amgen Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.